Colivelin TFA (867021-83-8 free base)

Research use only, not for human use.

Colivelin (TFA) is a hybrid peptide composed of ADNF and AGA-(C8R)HNG17, a potent Humanin (HN) derivative.

Colivelin (TFA) is a hybrid peptide composed of ADNF and AGA-(C8R)HNG17, a potent Humanin (HN) derivative.(In Vitro):Colivelin (TFA) is a hybrid peptide composed of ADNF and AGA-(C8R)HNG17, a potent Humanin (HN) derivative. Humanin (HN) and its derivatives, such as Colivelin (TFA), suppress neuronal death induced by insults related to Alzheimer's disease (AD) by activating STAT3. Colivelin (TFA) completely suppresses death induced by overexpressed FAD-causative genes and A 1-43 at a concentration of 100 fM, whereas AGA-(C8R)HNG17 does so at a concentration of 10 pM.(In Vivo):Humanin (HN) and its derivatives, such as Colivelin (TFA) also ameliorate functional memory impairment of mice induced by anticholinergic drugs or soluble toxic amyloid-β (Aβ). Intracerebroventricular administration of Colivelin (TFA) not only completely suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, but also it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42.

Others

Other Targets

STAT3

——

——

--

2759.1

C119H206N32O35.C2HF3O2

>98% (HPLC)

H2O : 25 mg/mL (9.06 mM; Need ultrasonic)

——

(-20℃)

With Ice Pack

≥ 2 years